Transfusion of packed red blood cells (RBCs) has been linked to an increased risk of nosocomial infection and a state of relative immunosuppression (1). Although a necessary part of resuscitation for many patients, RBC transfusion is associated with an increased possibility of ventilator-acquired pneumonia (2,3) and secondary infections (4). Some authors have hypothesized that these adverse events are increased in patients undergoing massive transfusion (5), which may be due to a two-hit phenomenon, with injury serving as the first hit and RBC transfusion providing the second hit (6). An area of significant interest and a source of significant controversy is the role of storage duration in outcomes following RBC transfusion. Many of the deleterious effects of transfusion are thought to be amplified in older RBCs and may be related to changes in RBC membranes or in soluble mediators released from RBCs or leukocytes. Prospective and retrospective analyses have suggested an increased risk of mortality (7), multiple system organ failure (5), need for ICU stay (7), and, importantly, an increased risk of nosocomial infection associated with older RBCs compared with younger red cell units (4,8). Although recent randomized, prospective data suggest no difference in outcomes between fresh versus longer stored units, these studies were not performed in the setting of massive transfusion and focused on leukoreduced blood (9,10).
The constellation of biochemical and mechanical changes that occur in RBCs over the duration of storage has been termed the “storage lesion.” We and others have argued that at least some of the potential deleterious clinical effects assigned to the storage lesion mirror those seen with excessive innate immune activation (11). Elements within stored RBC units have the capacity to act as damage-associated molecular pattern (DAMP) proteins. DAMPs are endogenous mediators of inflammation, which contribute to activation of innate immune pathways. Excessive DAMP release as well as exogenous administration (12) has been linked to negative outcomes. Several DAMPs signal through the critical innate immune receptor toll-like receptor 4 (TLR4), a receptor also linked to host responses to pathogens (13). One such DAMP, and a key regulatory molecule in the host response to infection, is high mobility group box 1 (HMGB1) (12). HMGB1 is a non-histone DNA binding protein that is passively released from dead or dying cells or released by activated cells during inflammation and has an important role in the host inflammatory response (14). In experimental models of trauma, HMGB1 contributes to both pro-inflammatory responses (15) and immunosuppression (16). HMGB1 has been previously shown to be present in stored human RBC units (17); however, the effects of HMGB1 administration as part of transfused RBCs remain unexplored. Previous authors have shown that exogenous HMGB1 can attenuate host response to pathogens (18) through dysregulation of phagocytosis and bacterial clearance (18–20).
In this study, we hypothesize that the HMGB1 that accumulates in stored RBC units, when administered exogenously in large quantities such as would be possible in the setting of massive transfusion, can impair microbial clearance. To test this hypothesis, we will examine the in vitro effects of exogenous HMGB1 (both recombinant and contained within stored RBC units) on the phagocytosis of Escherichia coli by macrophages and inflammatory cytokine production. To test the in vivo relevance of these findings, we have devised a murine model of trauma and hemorrhage that involves resuscitation of mice with the acellular supernatant of stored human RBCs (containing HMGB1), followed by an infectious challenge to model the scenario of nosocomial infection.
MATERIALS AND METHODS
C57BL/6 WT mice (8–12 weeks, male) were purchased from the Jackson Laboratories (Bar Harbor, Maine). Mice were housed in accordance with University of Pittsburgh (Pittsburgh, Pa) and National Institutes of Health (NIH; Bethesda, Md) animal care guidelines in specific pathogen-free conditions with 12-h light–dark cycles and free access to standard feed and water. All animal experiments were approved conducted in accordance with the guidelines set forth by the Animal Research and Care Committee at the University of Pittsburgh.
Human RBC and macrophage experiments
Following approval of the Institutional Review Board (PRO08010232) at the University of Pittsburgh, whole blood was collected from healthy volunteers following informed consent. Samples were stored in a de-identified fashion in accordance with IRB regulations. Experimental details for individual assays using human cells are outlined below.
Packed RBC supernatant preparation
The fresher (5 day) and older (42 day) packed RBC units preserved in CPD/AS-5 were acquired from the Institute for Transfusion Medicine and the Central Blood Bank with IRB approval (PRO09100378). RBCs were maintained under FDA mandated storage conditions throughout the duration of storage. For analysis, 10 (10) units were randomly selected from the indicated day of storage. Stored units underwent gentle centrifugation 2,000 × G, 4C] to separate the supernatant from cellular component. The acellular supernatants of these packed RBC units were stored at −80C for future use. All experiments utilized nonleukoreduced RBC units except for quantification of HMGB1, where, as indicated, leukoreduced PRBC supernatant was included for comparison.
Peritoneal macrophage Isolation
Brewer thioglycollate (2 mL, 3%; Sigma Aldrich Corp, St. Louis, Mo) was injected intraperitoneally (i.p.) in C57BL/6 mice to stimulate macrophage recruitment. After 5 days, a peritoneal wash was performed with 0.2 mM RPMI-EDTA solution to collect peritoneal macrophages (PM). Cells were subsequently washed twice with phosphate buffered saline, counted, and suspended in RPMI media. Cells were plated immediately for use.
E coli growth and dilution
E coli (ATCC 25922, American Type Culture Collection, Manassas, Va) were incubated in trypticase soy broth (TSB) at 37°C for 18 h. Bacteria were collected by centrifugation and washed twice in PBS. Using spectrophotometry, bacterial stock was diluted to ∼1 × 108 colony forming units (CFU)/mL. This sample was then serially diluted and inoculated at varying doses as outlined later.
Macrophage Coculture and bacterial clearance experiment
Peritoneal macrophages (PMs) were plated in 96-well plates at a concentration of 5 × 105 cells/well. PMs were cocultured for 6 h with either media alone or 20% D5 or D42 PRBC supernatant at 37oC and 5% CO2. After the 6-h coculture, ∼1 × 103E coli were added for 2 h again at 37oC and 5% CO2. After the 2-h incubation, E coli CFUs were determined by serial dilution of the supernatant and plating on TSB agar plates and counting after 18-h incubation. For evaluation of the effect of HMGB1, PMs were cocultured in media with either recombinant HMGB1, generated as we have previously described (15) at concentrations of 1, 2, 5 μg/mL or bovine serum albumin (BSA) at similar concentrations as control at 37oC and 5% CO2 for 6 h followed by E coli inoculation and determination of bacterial clearance as described above. Finally, PMs were cocultured in media with either an anti-HMGB1 neutralizing antibody (gift from Dr Kevin Tracey, Feinstein Institute for Medical Research, Manhasset, NY) at a concentration of 2.5 ug/mL or nonimmune rabbit IgG (Sigma-Aldrich, St. Louis, Mo) control at the same concentration and the bacterial clearance model was carried out as described.
RAW 264.7 experiments
RAW 264.7 macrophages were cultured and plated in 48-well plates at a concentration of 2 × 105 cells/well. Macrophages were cocultured for 3 h with either media alone or 20% D5 or D42 PRBC supernatant 37oC and 5% CO2. After 3-h coculture, macrophages were stimulated with Ultrapure lipopolysaccharide (LPS) derived from E coli (0111:B4, List Biological Laboratories Inc, Vandell Way, Calif) at a concentration of 0.01 ug/mL or media as previously described (19). After a total of 6 h cells were harvested and RNA extracted for IL-6 and TNF-α expression analysis by RT-PCR.
Quantitative real-time PCR
RNA was isolated from RAW 264.7 macrophages using the RNeasy kit (Qiagen, Hilden, Germany) and reverse transcribed to cDNA using Clontech cDNA synthesis kit (Clontech, Mountain View, Calif). Quantitative real-time PCR was performed as previously described using Bio-Rad CFX System using primers verified for IL-6 and TNF-α (21). Expression levels are expressed as fold change relative to the housekeeping gene GAPDH.
Human macrophage isolation and bacterial clearance
Human monocyte-derived macrophages (HMDM) were prepared from blood of healthy adult volunteers. First, peripheral blood mononuclear cells were fractionated by Ficoll-Paque density gradient centrifugation (GE Healthcare, Buckinghamshire, United Kingdom). CD14-positive monocytes were then selected by magnetically labeled beads, according to the manufacturer's instructions, using human CD14 MicroBeads, LS columns (Miltenyi Biotec, Auburn, Calif). CD14 + monocytes were cultured and differentiated into macrophages over 9 days in RPMI-1640 supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 mg/mL streptomycin, and 10 ng/mL M-CSF (R&D, Minneapolis, Minn). Cells were grown at 37°C in 5% CO2. Medium was half changed at the 3rd, 5th, and 7th day. After 9 days, differentiated macrophages were scraped, resuspended in antibiotic-free RPMI-1640 (10% FBS), and plated in a 96-well plate at a concentration of 1 × 105 cells/well. The coculture and bacterial clearance experiments were then conducted as described earlier.
The effect of older versus fresher PRBC supernatant was assessed with the Vybrant Phagocytosis Assay Kit (Thermo Fischer, V-6694, Waltham, Mass). Briefly, per manufacturer's recommendations, PMs were plated on a 96-well plate at a concentration of 1 × 106 cells/well. PMs were cocultured with media, D5, or D42 PRBC supernatant as described above for 6 h. Following coculture incubation all media was removed and PMs were inoculated with fluorescein-labeled E coli for 2 h. Next, trypan blue was added to quench extracellular fluorescent E coli and the plate was read. The effect of the D5 and D42 supernatant was calculated as a percentage compared with the control media reading (arbitrarily set at 100%).
Trauma and hemorrhagic shock (THS) model
Mice were anesthesized with isofluorane anesthesia. The femoral artery was cannulated with tubing connected to a blood pressure monitor. Polytrauma consisted of bilateral pseduofracture and liver crush injury. As previously described, pseudofracture is performed by injection of 0.15 cc of bone matrix, prepared from donor mice tibia and femur that is crushed and suspended in PBS, into the posterior muscles of the thigh (22). Liver crush was performed by a midline laparotomy, exposure of the right middle lobe of the liver, which was crushed four times with a 12.5 cm curved hemostat. Hemorrhage was performed by removal of 25% of circulating blood volume (based on 80 mL blood/kg body weight) via a closed cardiac puncture with a 1 cc syringe and 30-gauge needle. The laparotomy was closed and the mice were allowed to recover for 2 h. Upon awakening they were given buprenorphine (1 mg/kg) for analgesia. After the 2-h recovery, mice were resuscitated with Ringer lactate solution (LR), D5 PRBC supernatant, or D42 PRBC supernatant at a volume of three times the hemorrhage volume. Sham mice underwent groin exploration and femoral artery cannulation without polytrauma or hemorrhagic shock.
Twenty-four hours after THS, mice were inoculated via intraperitoneal injection with 5 × 104 CFU E coli(23). Twenty-four hours after E coli inoculation, mice were sacrificed by cardiac puncture technique. Peritoneal washings were obtained, serially diluted, plated on TSB agar plates, and cultured overnight at 37oC. The following day CFUs were counted.
Quantification of HMGB1
HMGB1 concentration was determined from the supernatant of packed RBC via ELISA (Shino-test; Tokyo, Japan). Flow cytometry was performed prior to centrifugation from blood pooled from three random samples for FACS analysis of HMGB1 following permeabilization (identified using PE conjugated human anti-HMGB1, 2.5 ug/mL (Biolegend, San Diego, Calif) expression on leukocytes (identified using FITC anti-CD45, 1 ug/mL (Biolegend) and RBCs (identified using FITC human anti-235b, 2.5 ug/mL (Biolegend)). Flow cytometry was performed using a FACSCanto flow cytometer using DIVA software (BD Biosciences, San Jose, Calif).
All data are presented as mean ± SD for n ≥3 unless stated otherwise in the figure legends. Statistical significance was determined with the 2-tailed Student t test or 1-way ANOVA with Tukey post hoc test using Graph Pad Prism software (GraphPad). A P value of less than 0.05 was considered significant.
RBC supernatant inhibits bacterial clearance and impairs macrophage function
The ability of peritoneal macrophages to clear pathogens was assessed in vitro in the presence of fresher and older RBC supernatants. E coli were cultured with thioglycollate-stimulated peritoneal phagocytes that were exposed to fresher or older RBC supernatants, while cell culture media treated with storage preservative alone was used as a control. As demonstrated in Figure 1, there was no significant change in microbial clearance from macrophages cultured with fresher RBC supernatant (CFU/mL, values are 107, 697.5 ± 185.5 vs. 755.0 ± 157.0, P = 0.304). However, pretreatment of macrophages with older RBC supernatant significantly impaired the clearance of E coli, resulting in higher CFUs (indicating less clearance of bacteria) (CFU/mL ×107: 930.6 ± 133.8, P = 0.0017 vs. control). Importantly, there were no significant differences in the number of peritoneal macrophages post-treatment, nor were there any significant changes postincubation with bacteria in any of the treatment groups (data not shown). To assess the effects of RBC supernatant on cytokine gene expression by macrophages, we pretreated isolated macrophages with RBC supernatant as above and then exposed the cells to LPS to induce cytokine message production. As demonstrated in Figure 1B and C using RT-PCR with values relative to GAPDH, supernatants from both fresher and older RBC markedly impaired the gene expression of IL-6 and TNF-α by macrophages, with the effects most pronounced with the older RBC supernatant. Of note, gene expression, as demonstrated by others, does not necessarily correspond to protein production or cytokine release (24). Multiple concentrations of LPS were tested in the system with consistent inhibition of cytokine gene expression by D42 supernatant, although inhibition by D5 supernatant could be overcome when LPS concentration reached 1 ug/mL (data not shown).
To determine whether the impaired clearance of microbes was due specifically to phagocytosis, we utilized a commercially available phagocytosis assay using peritoneal macrophages incubated with fluorescent E coli to determine the rate of internalization. Pre-incubation with RBC supernatant significantly inhibited phagocytosis of E coli, with the most pronounced effect occurring in the macrophages exposed to day 42 supernatant (Fig. 1D).
Soluble factors from older RBC supernatant impair microbial clearance after THS
The transfusion of packed RBC units of older storage age has been shown to increase the infectious complications following trauma (25). Following the identification of impaired clearance of E coli by macrophages treated with older (42-day old) RBC supernatant, we next sought to explore the in vivo relevance of these findings in a murine model of trauma and hemorrhage. The supernatant of fresher (5 day) or older (42 day) RBC was used as resuscitative fluid to evaluate role of soluble mediators in the packed RBC units in bacterial clearance following experimental trauma. The volume of supernatant (15 cc/kg) was chosen to reflect a massive transfusion resuscitation to account for the significant blood loss in our model (16). Mice were injected with E coli at 24 h following THS. Mice resuscitated with supernatant from older RBC showed impaired clearance of E coli compared with mice resuscitated with supernatant from fresher RBC or Lactated Ringer [CFU/mL ×107 older RBC supernatant: 36.6 ± 10.2 vs. fresher RBC supernatant: 17.3 ± 6.8 vs. LR: 19.2 ± 4.4, sham (out of box control): 3.7 ± 2.2 P < 0.05] (Fig. 2). There was no difference in survival of animals through the duration of the model.
Older blood supernatant inhibits human macrophage clearance of E coli
HMDM were prepared from blood of healthy adult volunteers and treated with either media alone, day 5 supernatant, or day 42 supernatant. Following incubation with E coli, microbial clearance was assessed. Similar to the findings using murine macrophages, bacterial clearance was markedly inhibited (resulting in higher measure CFU, or more residual bacteria) following exposure to day 42 supernatant (CFU/mL ×107, media 260.7 ± 39 vs. day 5 SN 224.3 ± 54 vs. day 42 SN 389.6 ± 98, P <0.0001 for day 42 vs. media by ANOVA) (Fig. 2C).
HMGB1 is present in RBC supernatants
HMGB1 has been shown to be a key mediator in the pathogenesis of organ injury and a contributor to immunosuppression following trauma and hemorrhagic shock. To determine if extracellular levels of HMGB1 increased with longer RBC storage, HMGB1 levels were measured in supernatants of stored RBC over time. Whole blood was collected from healthy volunteers without leukoreduction and the mean HMGB1 level was determined to be 0.9519 ng/mL as a baseline for circulating levels of HMGB1 prior to blood storage. We found that there was a significant increase in supernatant HMGB1 levels over time (fresher: 69.147 ng/mL ± 2.2 vs. older: 238.32 ng/mL ± 13.5, P <0.0001) (Fig. 3). To assess whether the source of HMGB1 in the RBC supernatants was derived from the leukocyte component of stored RBCs, we performed the same studies in leukoreduced (LR) RBCs and found lower levels of HMGB1. Despite the reduction in concentration, an increase in HMGB1 levels was still observed with storage (fresher LR: 13.636 ng/mL ± 0.43 vs. older LR: 87.180 ng/mL ± 2.02, P <0.001). Because HMGB1 release was seen even in leukoreduced RBC we assessed whether HMGB1 could be found associated with the actual RBC. FACS analysis for CD-235a allowed for sorting of RBCs, which were stained for HMGB1 and analyzed. Shown in Figure 3 are representative tracings from FACS analysis of permeabilized leukocytes (B) and RBCs from randomly selected, non-leukoreduced day 42 units (C). Leukocytes were chosen as a positive control and express robust levels of HMGB1, which is not associated with RBCs. RBCs of shorter storage duration were also tested and also failed to express HMGB1 (data not shown).
HMGB1 derived from RBC supernatants inhibits bacterial clearance
It has been previously demonstrated that HMGB1 inhibits phagocytosis in pulmonary leukocytes (19). Given our findings of impaired bacterial clearance after trauma, transfusion, and E coli infection, and given the observation that HMGB1 accumulates in stored RBC units, we sought to assess whether HMGB1 could inhibit bacterial clearance in peritoneal macrophages. Peritoneal phagocytes were cultured with E coli after incubating with either recombinant HMGB1 or BSA as a control protein. As shown in Figure 4A, HMGB1 strongly inhibited bacterial clearance, as measured by an increase in CFUs in macrophages treated with HMGB1. (CFU ×107 BSA: 300.7 ± 15.9 vs. HMGB1: 443.0 ± 14.8, P <0.05). Having confirmed that exogenous administration of HMGB1 can reduce clearance of bacteria, we next sought to remove HMGB1 from the RBC supernatant to see whether we could reverse the effect on bacterial clearance seen with exposure of macrophages to older RBC supernatants. Treatment of older supernatant with a HMGB1 neutralizing antibody resulted in a significant and marked increase in bacterial clearance by peritoneal macrophages (as measured by decreased remaining bacteria/CFU) as compared with IgG control (CFU ×107 IgG: 983.7 ± 52.1 vs. anti-HMGB1: 810.2 ± 46.0, P <0.05). These data support the hypothesis that HMGB1 present in stored RBC units inhibits phagocytosis by peritoneal macrophages.
The transfusion of stored RBC units has been linked to an increase in nosocomial infection in patients following injury (1–4), although the mechanism by which this occurs remains largely unexplored. We and others have previously observed that numerous components of stored RBCs act as innate immune modulators (11,26), and it is well characterized that innate immune signaling on macrophages regulates their function in the setting of trauma (26,27). Here, we identify the DAMP, HMGB1 as a potential inhibitor of macrophage phagocytosis following accumulation in stored RBC units. HMGB1 has previously been identified as an inhibitor of phagocytosis of apoptotic neutrophils through the binding of phosphatidyl serine (20) and is well recognized as an important innate immune signal in the setting of trauma (28,29) and sepsis (30). HMGB1 has also been shown to induce pyroptosis in macrophages (31). High concentrations of HMGB1 have been detected early in the inflammatory response to trauma and hemorrhage (12), and multiple animal models have characterized the deleterious effects of exogenous HMGB1 administration (12,28,32). The functional consequence of HMGB1 accumulation in stored RBCs was previously unknown but now appears to contribute to reduced inflammatory signaling and impaired microbial clearance.
In a series of in vitro experiments, we found that pretreatment of isolated murine macrophages with human RBC supernatant impaired E coli clearance. Following addition of a fixed volume of bacteria, more CFUs of E coli were obtained from macrophages pretreated with the supernatant of older (42-day old) but not fresher (5-day old) RBC units or control. Recovery of higher CFU counts suggests impaired phagocytosis and killing of bacteria (23). Keeping with the observation that RBC supernatants may impair macrophage function, we identify a reduction in the ability of peritoneal macrophages to express cytokines. Both IL-6 and TNFα gene expression in response to LPS challenge were reduced in both RBC supernatant treatment groups, although the reduction was most pronounced in the older (day 42) supernatant group. We sought to validate these findings in vivo by devising a two-hit model—trauma/hemorrhage followed by intraperitoneal inoculation with E coli. The two-hit approach of infection following hemorrhage has been utilized previously as a model of in vivo macrophage function in bacterial clearance (24). Resuscitation was performed using LR, fresher RBC supernatant, or older RBC supernatant. HMGB1 was shown to accumulate in stored RBC units, with the most pronounced effect in older RBC units (stored for 42 days). We show here that the source of the HMGB1 is predominantly leukocyte driven. RBCs were shown not to express HMGB1. The mechanism of HMGB1 release could be by leukocyte cell death, either necrosis or pyroptosis or active release following activation. Clearance of bacteria was substantially reduced in mice receiving treatment with older RBC supernatant. The finding of impaired microbial clearance was attributed to HMGB1, as a neutralizing antibody to HMGB1 was sufficient to reverse the increase in CFU, while exogenous administration of HMGB1 to media treated macrophages reproduced the findings seen with stored RBC supernatants. As an initial suggestion of potential relevance beyond the murine studies, we also have shown that day 42 supernatant inhibited bacterial clearance by human macrophages.
Previous authors have validated the use of stored human RBC supernatant in murine studies (16). A two-hit model of murine trauma and intraperitoneal infection allowed for the assessment of bacterial clearance following induction of inflammation, which has previously been shown to have important implications on macrophage function (23). A paucity of literature exists to explore the physiological effects of RBC transfusion on immune function in the setting of massive hemorrhage. The volume of RBC supernatant was chosen to best model a murine “massive transfusion.” The acellular supernatant fraction was chosen as this was the fraction most likely to contain soluble HMGB1, as confirmed by the absence of HMGB1 on RBCs as shown by FACS analysis. Although a smaller volume of HMGB1 was still detected in leukoreduced RBC units, this could still be from residual leukocytes, as leukoreduction techniques have been shown to leave some residual leukocyte component (<5,000,000 WBCs/unit) and/or result in leukocyte injury/death and the potential for HMGB1 release (33). Furthermore, transfusion of the acellular human supernatant minimizes issues of xenogeneic immune activation, allowing for the ability to test the effects of human HMGB1, albeit necessarily in a murine model of trauma. In addition, we pooled 10 units of RBCs to create the supernatant used in these assays to minimize issues with inter-donor variability. The identification of potential immunomodulatory substances in stored RBC units may be of importance if the observational data suggesting an increase in nosocomial infection associated with older RBC transfusion persists in randomized prospective analyses of this patient population.
This study has a number of limitations. We sought to use human RBCs to assess the potential for inflammatory components within the stored units; however, the effects of human RBC supernatant within a murine system cannot be directly extrapolated to patient care. The finding of similar effect on human macrophages somewhat supports the validity of the observed effect of aged supernatant; however, mechanistic studies in human cell lines would be required to understand potential clinical effects in further detail. Additionally, prior authors have shown that gene expression, which we show to be altered by exposure to RBC supernatant, does not necessarily correlate with cytokine release in macrophages (24). Although we used an acellular fraction, issues of immune stimulation cannot be excluded, although one would expect these to be the same for both durations of storage tested. In phagocytosis assays (Fig. 1D), the effect of day 5 supernatant was more pronounced than on any of the other clearance assays performed (such as Fig. 1A). Potential explanations for this difference include differences in the bacterial strain (the phagocytosis assay required a fluorescent labeled E coli) as well as different endpoints (CFU vs. fluorescent intensity) for the assays. We do not provide a mechanism for the HMGB1 effect in the present analysis. Multiple previous studies have evaluated the role of HMGB1 signaling through known innate immune receptors including TLR4 (12,13,15,28,34,35), TLR2, and the receptor for advanced glycation end products (RAGE) (13). We have recently shown that platelets express HMGB1 (35), which is implicated in thrombus formation and cell signaling, but this effect does not appear to be shared by RBCs according to our findings here. The specific effects of HMGB1 on macrophage phagocytosis are thought to occur through interference of the αvβ3 integrin of phagocytes (20). However, high levels of HMGB1 can also induce pyroptosis in macrophages through a RAGE-dependent mechanism (31). In these assays, we have chosen to focus on clearance of a gram-negative bacterium, which is a common nosocomial pathogen (36). However, our findings may be specific to E coli and potentially may not be extrapolated to other forms of nosocomial infection; furthermore, it is not explicitly clear if impaired phagocytosis can be causally linked to the development of infection in this setting. In addition, the concentrations of recombinant HMGB1 used in the in vitro assays are substantially higher than measured concentrations in vivo. Although similar to concentrations used in other published studies (35), the need to use higher doses of recombinant protein to elicit an effect likely represents key differences in structure and function between recombinant and endogenous proteins. Nevertheless, the biological potential for stored RBCs to modulate macrophage function through HMGB1 adds to the body of biochemical evidence that defines the storage lesion.
In summary, we described the release of HMGB1 from RBC units throughout the duration of storage in a process largely dependent upon the leukocyte fraction. The accumulated HMGB1 was shown to be biologically active and impaired macrophage function and resulted in impaired microbial clearance in a two-hit model of trauma/hemorrhage and E coli infection. These findings add to the growing body of literature regarding the effect of RBC storage, with particular emphasis on the role of the leukocyte. Release of inflammatory mediators such as HMGB1 may play a role in innate immune activation following RBC transfusion (11) and could have implications in the development of infectious and inflammatory complications. Strategies to remove HMGB1 from stored RBC could reduce the impact of massive transfusion on immune function. A dedicated study of the clinical outcomes of stored RBC transfusion in the setting of trauma and massive hemorrhage is warranted given the clinical controversy surrounding the effects of RBC storage.
The authors acknowledge the contribution of Dr Rami Namas to the measurement of HMGB1 levels in healthy volunteers as well as Mrs Lauryn Kohut for her expertise in animal model work.
1. Shorr AF, Jackson WL. Transfusion practice and nosocomial infection: assessing the evidence. Curr Opin Crit Care
2005; 11 5:468–472.
2. Earley AS, Gracias VH, Haut E, Sicoutris CP, Wiebe DJ, Reilly PM, Schwab CW. Anemia management program reduces transfusion volumes, incidence of ventilator-associated pneumonia, and cost in trauma patients. J Trauma
2006; 61 1:1–5.
3. Bochicchio GV, Napolitano L, Joshi M, Bochicchio K, Shih D, Meyer W, Scalea TM. Blood product transfusion and ventilator-associated pneumonia in trauma patients. Surg Infect (Larchmt)
2008; 9 4:415–422.
4. Juffermans NP, Prins DJ, Vlaar AP, Nieuwland R, Binnekade JM. Transfusion-related risk of secondary bacterial infections in sepsis patients: a retrospective cohort study. Shock
2011; 35 4:355–359.
5. Sihler KC, Napolitano LM. Complications of massive transfusion
2010; 137 1:209–220.
6. Hod EA, Zhang N, Sikol SA, Wojczyk BS, Francis RO, Ansaldi D, Francis KP, Della-Latta P, Whittier S, Hendrickson JE, et al. Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood
2010; 115 21:4284–4292.
7. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ. The CRIT study: anemia and blood transfustion in the critically ill—current clinical practice in the United States. Crit Care Med
2004; 32 1:39–52.
8. Vandromme MJ, McGwin G Jr, Marques MB, Kerby JD, Rue LW 3rd, Weinberg JA. Transfusion and pneumonia in the trauma intensive care unit: an examination of the temporal relationship. J Trauma
2009; 67 1:97–101.
9. Lacroix J, Hebert PC, Fergusson DA, Tinmouth A, Cook DJ, Marshall JC, Clayton L, McIntyre L, Callum J, Turgeon AF, et al. ABLE Investigators, Canadian Critical Care Trials Group. Age of transfused blood in critically ill adults. N Engl J Med
2015; 372 15:1410–1418.
10. Steiner ME, Ness PM, Assmann SF, Triulzi DJ, Sloan SR, Delaney M, Granger S, Bennett-Guerrero E, Blajchman MA, Scavo V, et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med
2015; 372 15:1419–1429.
11. Neal MD, Raval JS, Triulzi DJ, Simmons RL. Innate immune activation after transfusion of stored red blood cells. Transfus Med Rev
2013; 27 2:113–118.
12. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med
2005; 201 7:1135–1143.
13. Aneja RK, Tsung A, Sjodin H, Gefter JV, Delude RL, Billiar TR, Fink MP. Preconditioning with high mobility group box 1
(HMGB1) induces lipopolysaccharide (LPS) tolerance. J LeukocBiol
2008; 84 5:1326–1334.
14. Andersson U, Tracey KJ. HMGB1 in sepsis. Scand J Infect Dis
2003; 35 9:577–584.
15. Levy RM, Mollen KP, Prince JM, Kaczorowski DJ, Vallabhaneni R, Liu S, Tracey KJ, Lotze MT, Hackam DJ, Fink MP, et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol
2007; 293 4:R1538–R1544.
16. Donadee C, Raat NJ, Kanias T, Tejero J, Lee JS, Kelley EE, Zhao X, Liu C, Reynolds H, Azarov I, et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation
2011; 124 4:465–476.
17. Peltz ED, Moore E, Eckels PC, Damle SS, Tsuruta Y, Johnson JL, Sauaia A, Silliman CC, Banerjee A, Abraham E. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock
2009; 32 1:17–22.
18. Entezari M, Weiss DJ, Sitapara R, Whittaker L, Wargo MJ, Li J, Wang H, Yang H, Sharma L, Phan BD, et al. Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis. Mol Med
2012; 18 1:477–485.
19. Patel VS, Sitapara RA, Gore A, Phan B, Sharma L, Sampat V, Li JH, Yang H, Chavan SS, Wang H, et al. High Mobility Group Box-1 mediates hyperoxia-induced impairment of Pseudomonas aeruginosa clearance and inflammatory ling injury in mice. Am J Respir Cell MolBiol
2013; 48 3:280–287.
20. Friggerl A, Yang Y, Banerjee S, Park YJ, Liu G, Abraham E. HMGB1 inhibits macrophage activity in efferocytosis through binding to the alphavbeta3-integrin. Am J Physiol Cell Physiol
2010; 299 6:C1267–C1276.
21. Overbergh L, Valckx D, Waer M, Mathieu C. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine
1999; 11 4:305–312.
22. Darwiche SS, Kobbe P, Pfeifer R, Kohut L, Pape H, Billiar T. Pseudofracture: an acute peripheral trauma model. J Vis Exp
23. Maung AA, Fujim S, MacConmara MP, Tajima G, McKenna AM, Delisle AJ, Stallwood C, Onderdonck AB, Mannick JA, Lederer JA. Injury enhances resistance to Escherichia coli infection by boosting innate immune system function. J Immunol
2008; 180 4:2450–2458.
24. Zellweger R, Zhu X-H, Wichmann MW, Ayala A, DeMaso CM, Chaudry IH. Prolactin administration following hemorrhagic shock improves macrophage cytokine release capacity and decreases mortality from subsequent sepsis. J Immunol
25. Belizaire RM, Makley AT, Campion EM, Sonnier DI, Goodman MD, Dorlac WC, Friend LA, Lentsch AB, Pritts TA. Resuscitation with washed aged packed red blood cell units decreases the proinflammatory response in mice after hemorrhage. J Trauma Acute Care Surg
2012; 73 (2 suppl 1):S128–S133.
26. Hod EA, Spitalnik. Stored red blood cell transfusions: iron, inflammation, immunity, and infection. Transfus Clin Biol
2012; 19 3:84–89.
27. Naito Y, Takagi T, Higashimura Y. Heme oxygenase-1 and anti-inflammatory M2 macrophages. Arch Biochem Biophys
28. Fan J, Li Y, Levy RM, Fan JJ, Hackam DJ, Vodovotz Y, Yang H, Tracey KJ, Billiar TR, Wilson MA. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol
2007; 178 10:6573–6580.
29. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med
2008; 14 (7–8):476–484.
30. Huang W, Tang Y, Li L. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine
2010; 51 2:119–126.
31. Xu J, Jiang Y, Wang J, Shi X, Liu Q, Liu Z, Li Y, Scott MJ, Xiao G, Li S, et al. Macrophage endocytosis of high-mobility group box 1 triggers pyrooptosis. Cell Death Differ
32. Bauer EM, Shapiro R, Zheng H, Ahmad F, Ishizawar D, Comhair SA, Erzurum SC, Billiar TR, Bauer PM. High Mobility group box 1
contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol Med
2013; 18 1:1509–1518.
33. Sharma RR, Marwaha N. Leukoreduced blood components: advantages and strategies for its implementation in developing countries. Asian J Transfus Sci
2010; 4 1:3–8.
34. Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z, Peng X, Stolz DB, Geller DA, Rosengart MR, Billiar TR. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med
2007; 204 12:2913–2923.
35. Vogel S, Bodenstein R, Chen Q, Feil S, Feil R, Rheinlaender J, Schaffer TE, Bohn E, Frick JS, Borst O, et al. J Clin Invest
2015; 125 12:4638–4654.
36. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD 2nd, Kreisel D, Krupnick AS, et al. JAMA
2011; 306 23:2594–2605.